Latest Stories
Featured Stories
Explore inspiring journeys of recovery and resilience as patients share their experiences with Padaav’s root-cause-focused, evidence-based Ayurvedic treatments, highlighting the power of personalized care and holistic healing.
Feedback
All Stories
Delve into the heartfelt experiences of patients who have transformed their health and lives with Padaav’s research-backed Ayurvedic care, showcasing the impact of addressing root causes for lasting recovery.
Surendra Rathaur
Acute Pancreatitis
Ahmedabad, Gujarat
Ahmedabad, Gujarat, India — Surendra Rathaur, a 34-year-old Senior Software Engineer from A…
Samip Desai
Chronic Calcific Pancreatitis
Ahmedabad, Gujarat
Ahmedabad, Gujarat, India — Samip Desai, a 38-year-old restaurateur from Ahmedabad, embarke…
Hardi Nayak
Acute Pancreatitis
Gandhinagar, Gujarat
Gandhinagar, Gujarat, India — Hardi Nayak, a 12-year-old student from Gandhinagar, found he…
Raj Khanapara
Chronic Pancreatitis
Rajkot, Gujarat
Rajkot, Gujarat, India — For Raj Khanapara, a 26-year-old businessman from Rajkot, the onse…
Ajay Vaghela
Recurrent Acute Pancreatitis
Ahmedabad, Gujarat
Ahmedabad, Gujarat, India — For Ajay Vaghela, a 30-year-old petrol pump business owner from…
Aditya Jain
Acute on Chronic Pancreatitis
Ahmedabad, Gujarat
Ahmedabad, Gujarat, India — At the age of 15, Aditya Jain, a student from Ahmedabad, faced …
Research
Our Research
At Padaav, alongside delivering unparalleled patient care and promoting holistic health, we are committed to advancing Ayurveda by actively participating in research and contributing to its growing body of knowledge.
Response to Ayurvedic therapy in the treatment of migraine without aura
A study on 204 migraine patients using an Ayurvedic Treatment Protocol (AyTP) showed 35.2% had complete relief, 35.2% had mild episodes without medication, and 70.5% experienced reduced pain frequency and intensity. The preliminary results suggest the AyTP may be effective, though the study's design limits firm conclusions.
Acute and Sub acute Toxicity Study of Ayurvedic Formulation (AYFs) Used for Migraine Treatment
This study tested the safety of five Ayurvedic formulations for migraine prevention in rats and mice. Acute and sub-acute toxicity studies showed no toxic effects at doses up to 10 times the human dose. A slight mortality in high-dose groups was unrelated to treatment. The formulations are considered safe, but further chronic toxicity studies are needed.
Symptom-free status after prolonged suffering with refractory chronic migraine: A case report
A 37-year chronic refractory migraine sufferer experienced significant relief in pain, symptoms, and overall well-being after nine months of Ayurvedic treatment, highlighting its potential therapeutic benefits.
Sustainable Effect of Ayurvedic Formulations in the Treatment of Nutritional Anemia in Adolescent Students
This study evaluated the impact of Ayurvedic treatments (Sootshekhar Rasa and Sitopaladi Churna) on nutritional anemia in 1322 adolescent students in Dehradun. After 90 days of treatment, significant hemoglobin improvements were seen in the treatment groups, especially those receiving a daily dose of 250 mg SR and 400 mg SC. The study concluded that this combination effectively improves anemia in adolescents without adverse effects.
Scientific validated approach for application of Mandura bhasma A review
Mandura (iron rust) is purified and calcined in Ayurveda to create Mandura Bhasma, used for conditions like spleen and liver enlargement, jaundice, oedema, and anemia. Our study found that Prak-20 aligns with the classical dose schedule for Mandura Bhasma.
Clinical Intervention of Ayurvedic Treatment in the Patients of Recurrent Acute/Chronic Pancreatitis
The study of 1233 acute pancreatitis patients found that 12.9% experienced oral feeding intolerance (OFI). Risk factors included younger age, male sex, alcohol use, smoking, non-biliary etiology, and SIRS at 48h. SIRS at 48h (OR 2.85) and non-biliary etiology (OR 1.77) were independently linked to OFI, with biliary etiology being protective.